Posted by Michael Wonder on 18 Dec 2024
Ublituximab for the treatment of patients with relapsing multiple sclerosis
18 December 2024 - NICE has published final evidence-based recommendations on the use of ublituximab (Briumvi) for the treatment of adults with relapsing multiple sclerosis.
Ublituximab is recommended as an option for the treatment of adults with relapsing-remitting multiple sclerosis, defined as active by clinical or imaging features, only if Neuraxpharm Pharmaceuticals provides it according to the commercial arrangement.
